FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.